- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Alaunos Therapeutics (TCRT)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.94 mm | 1.94 mm | 1.94 mm | 1.94 mm | 1.94 mm | 1.94 mm |
| Cash burn (monthly) | 313.67 k | (no burn) | 395.67 k | 339.42 k | 281.33 k | 242.42 k |
| Cash used (since last report) | 1.35 mm | n/a | 1.70 mm | 1.46 mm | 1.21 mm | 1.04 mm |
| Cash remaining | 587.27 k | n/a | 234.15 k | 476.38 k | 726.50 k | 894.09 k |
| Runway (months of cash) | 1.9 | n/a | 0.6 | 1.4 | 2.6 | 3.7 |
| 13F holders | Current |
|---|---|
| Total holders | 33 |
| Opened positions | 11 |
| Closed positions | 4 |
| Increased positions | 2 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 161.39 mm |
| Total shares | 15.94 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| White Rock Capital Management | 9.63 mm | $23.30 mm |
| Hardie Robert D. | 6.24 mm | $0.00 |
| BLK BlackRock | 21.35 k | $40.68 mm |
| Vanguard | 20.97 k | $39.85 mm |
| Geode Capital Management | 15.22 k | $28.92 mm |
| UBS UBS | 7.87 k | $14.99 mm |
| C Citigroup | 1.60 k | $3.03 mm |
| Tower Research Capital | 1.15 k | $2.19 mm |
| MS Morgan Stanley | 1.05 k | $1.99 mm |
| Advisor | 857.00 | $2.75 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Jan 26 | Michael Allen Jerman | Common Stock | Grant | Acquire A | No | No | 2.89 | 5,406 | 15.62 k | 9,589 |
| 12 Jan 26 | Postma Robert W | Common Stock | Grant | Acquire A | No | No | 2.89 | 5,622 | 16.25 k | 43,872 |
| 12 Jan 26 | Jaime Vieser | Common Stock | Grant | Acquire A | No | No | 2.89 | 5,839 | 16.87 k | 32,338 |
| 21 Nov 25 | Postma Robert W | Common Stock | Grant | Acquire A | No | No | 3.16 | 5,142 | 16.25 k | 38,250 |
| 21 Nov 25 | Michael Allen Jerman | Common Stock | Grant | Acquire A | No | No | 3.16 | 4,183 | 13.22 k | 4,183 |